SNY
OtherSanofi
$43.77+0.41 (+0.95%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SNY Today?
No stock-specific AI insight has been generated for SNY yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$104.9B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding2.40B
SNY News
51 articles- The Agencies Building Pharma's Next Decade Just Picked Their Software: Daily Command Launches With 18 of the Industry's Most Senior Agency Leaders Already Inside ItYahoo Finance·May 7, 2026
- 75 of Pharma's Most Senior Marketers Just Walked Away From a $12 Billion Tool StackYahoo Finance·May 7, 2026
- RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YYahoo Finance·May 7, 2026
- Nexviazyme (Sanofi: avalglucosidase alfa-ngpt) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FYahoo Finance·May 7, 2026
- IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi LeadingYahoo Finance·May 7, 2026
- Vicore Pharma Elects Peter Guenter to its Board of DirectorsYahoo Finance·May 7, 2026
- Novavax, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A BreakoutYahoo Finance·May 6, 2026
- Sanofi’s Dynavax Deal Reshapes Vaccine Portfolio And Valuation NarrativeYahoo Finance·May 6, 2026
- Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1Yahoo Finance·May 6, 2026
- Novavax Reports First Quarter 2026 Financial Results and Operational HighlightsYahoo Finance·May 6, 2026
- BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance RaisedYahoo Finance·May 5, 2026
- Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoEAdvfn·May 5, 2026
- Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab RealityYahoo Finance·May 5, 2026
- Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialYahoo Finance·May 5, 2026
- Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patientsYahoo Finance·May 4, 2026
- European Equities Traded in the US as American Depositary Receipts Start Week LowerYahoo Finance·May 4, 2026
- A Look At Novavax (NVAX) Valuation As It Shifts To Licensing And Awaits Combo Vaccine DataYahoo Finance·May 2, 2026
- The 28th China Beijing International High-Tech Expo Grand Opening SoonYahoo Finance·May 2, 2026
- KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD CollaborationYahoo Finance·May 1, 2026
- Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just StartedGlobeNewswire Inc.·Apr 29, 2026
- 3 Mega-Cap Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%Investing.com·Apr 29, 2026
- Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobeNewswire Inc.·Apr 28, 2026
- AI Disruption in Lung Cancer Therapeutics Set to Transform Treatment Paradigms as Billion-Dollar Investments Drive InnovationGlobeNewswire Inc.·Apr 27, 2026
- HSBC Continental Europe: Pre Stabilisation NoticeGlobeNewswire Inc.·Apr 24, 2026
- Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsightGlobeNewswire Inc.·Apr 23, 2026
- Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôléeGlobeNewswire Inc.·Apr 22, 2026
- Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticariaGlobeNewswire Inc.·Apr 22, 2026
- Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfantsGlobeNewswire Inc.·Apr 22, 2026
- Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young childrenGlobeNewswire Inc.·Apr 22, 2026
- Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directeGlobeNewswire Inc.·Apr 18, 2026
- Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head studyGlobeNewswire Inc.·Apr 18, 2026
- France's 2026 Market Story Could Stay Centered On Luxury, Pharma And BanksBenzinga·Apr 17, 2026
- China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and SanofiGlobeNewswire Inc.·Apr 17, 2026
- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightGlobeNewswire Inc.·Apr 13, 2026
- Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticariaGlobeNewswire Inc.·Apr 13, 2026
- Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfantsGlobeNewswire Inc.·Apr 13, 2026
- Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage PipelineGlobeNewswire Inc.·Apr 10, 2026
- Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033GlobeNewswire Inc.·Apr 10, 2026
- Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032GlobeNewswire Inc.·Apr 10, 2026
Price Data
Open$43.61
Previous Close$43.36
Day High$43.96
Day Low$43.59
52 Week High—
52 Week Low—
Fundamentals
Market Cap$104.9B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding2.40B
About Sanofi
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—